Their drug-repurposing screen yielded 34 positive hits out of 414 clinically approved drug candidates tested, in monotherapies or drug-pairs, on a panel of 36 KRAS-mutant CRC PDOs. The gene discussed is KRAS; the disease is colorectal carcinoma.